Treatment with nivolumab (Opdivo) reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy, according to findings from the phase III ONO-4538-12 trial presented at the 2017 Gastrointestinal Cancers Symposium. – See more at: http://www.onclive.com/conference-coverage/gi-2017/salvage-nivolumab-improves-survival-in-advanced-gastricgej-cancer#sthash.VnjYm4Hk.dpuf
http://www.onclive.com/conference-coverage/gi-2017/salvage-nivolumab-improves-survival-in-advanced-gastricgej-cancer
Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer